#United States #New York #IceCure Medical #Cryoablation #ProSense

IceCure Medical to Attend the 2025 Maxim Growth Summit

IceCure Medical Ltd., a frontrunner in the development of minimally-invasive cryoablation technologies, has confirmed its participation in the upcoming Maxim Growth Summit scheduled for October 22-23, 2025, in New York City. This event provides an excellent platform for IceCure's leadership team, including CEO Eyal Shamir, to connect with institutional investors, share insights, and discuss the latest advancements in their technologies.

Recent Accomplishments

A key highlight for IceCure Medical is the recent FDA marketing authorization they received for their ProSense® Cryoablation System. This groundbreaking device represents the first of its kind approved for the local treatment of early-stage, low-risk breast cancer specifically in patients aged 70 and above, as well as in women who are not suitable candidates for surgery.

The ProSense® system offers a promising alternative to traditional surgical methods, using cryoablation technology to target tumors by freezing them, thus minimizing the need for invasive procedures. This innovative approach holds the potential to significantly alter the future of treatment protocols for low-risk early-stage breast cancer, establishing a new standard of care that could benefit countless patients.

Engagement Opportunities

During the summit, IceCure's management will provide comprehensive overviews covering the company's journey to regulatory approval, its commercial strategies, and other significant achievements in the U.S. and international markets. This initiative encourages investors to reach out through their Maxim sales representatives or directly via email to Michael Polyviou at [email protected] to schedule personalized meetings.

The Company's Vision

IceCure Medical is dedicated to advancing treatment options through its pioneering technologies, targeting benign and cancerous tumors through a cryoablation process that involves liquid nitrogen. With their sights set on breast, kidney, lung, and bone cancers, IceCure aims to redefine how medical professionals approach tumor treatment, making procedures easier, shorter, and less invasive for patients.

This milestone not only represents a significant leap for IceCure Medical but also underscores their commitment to innovating healthcare solutions that prioritize patient well-being. As the company prepares for engagement at the Maxim Growth Summit, stakeholders eagerly anticipate further developments that will emerge from their participation.

Looking Ahead

As IceCure Medical continues to build upon its success in cryoablation technology, the Maxim Growth Summit serves as an important venue for fostering connections that promote future growth and collaboration within the healthcare industry. Investors and healthcare professionals alike are invited to engage with IceCure to explore the vast potential that lies within their ground-breaking approaches to cancer treatment.

With a focus on expanding their market reach and enhancing awareness of their pioneering systems, IceCure Medical is well-positioned to lead the charge toward a future where cancer treatment is characterized by less invasiveness, increased efficiency, and improved outcomes for patients globally.